Key factors
symMYOS
exchUS
MCap1026.14K
Beta1.077
EPS-0.37
Div date0000-00-00
Yesterday
symMYOS
exchUS
close11.38
50 Day MA12.50
200 Day MA15.15
Target Price 3.75
Market Cap Mln1.026
Share statistics
Shares Outstanding12.19M
Shares Float6469.45K
Percent Institutions0.278
PercentInsiders46.51
SharesShort10597
Short Ratio0.09
Shares Short Prior Month57666
Short Percent0.170
Revenue TTM 1483.0K
Revenue Per Share TTM 0.141
Quarterly Revenue Growth YOY 38.60
Gross Profit TTM 635.0K
EBITDA-3768.0K
Diluted Eps TTM-0.34
earning
Operating Margin TTM -2.42
Earnings Share -0.37
Dividend
Dividend Date0000-00-00
Last Split Date 2014-02-10
Last Split Factor1:50
business
Enterprise Value Revenue8.530
Book Value /share 0.171
Price Book MRQ 6.089
Price Sales TTM 7.181
ProfitMargin -2.45
ReturnOnAssetsTTM -0.65
Gic GroupHousehold & Personal Products
Gic IndustryPersonal Care Products
Gic Sector Consumer Staples
Gic Sub Industry Personal Care Products
Industry Drug Manufacturers - Specialty & Generic
SectorHealthcare
ISIN US62857P1084
CIK 1402479
Code MYOS
CUSIP 049433105
Employer Id Number 90-0772394
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange OTCBB
Currency Symbol $
Type Common Stock
UpdatedAt 2020-11-22
is Delisted 1
Delisted Date 2020-11-18
Home Category Domestic
Fiscal Year End December
Full Time Employees15.0
IPODate 2010-05-03
International Domestic Domestic
MostRecent Quarter2020-09-30
Contact
NameMYOS RENS Technology Inc
Address45 Horsehill Road, Cedar Knolls, NJ, United States, 07927
Country NameUSA
Phone973 509 0444
Web URLwww.myosrens.com
MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The company primarily focuses on developing Fortetropin for the therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity, and muscular disorders. Its products include Qurr line of products to support muscle well-being and fitness; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform. It has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery of compounds and products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.